BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17689624)

  • 1. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial.
    Thorneycroft IH; Lindsay R; Pickar JH
    Am J Obstet Gynecol; 2007 Aug; 197(2):137.e1-7. PubMed ID: 17689624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women.
    Utian WH; Gass ML; Pickar JH
    Menopause; 2004; 11(3):306-14. PubMed ID: 15167310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.
    Hsia J; Criqui MH; Rodabough RJ; Langer RD; Resnick HE; Phillips LS; Allison M; Bonds DE; Masaki K; Caralis P; Kotchen JM;
    Circulation; 2004 Feb; 109(5):620-6. PubMed ID: 14769684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study.
    Ausmanas MK; Holinka CF; Ling YS; Christiansen C
    Climacteric; 2007 Aug; 10(4):306-13. PubMed ID: 17653957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
    J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.
    Limpaphayom KK; Darmasetiawan MS; Hussain RI; Burriss SW; Holinka CF; Ausmanas MK
    Climacteric; 2006 Jun; 9(3):204-14. PubMed ID: 16766434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ovarian hormones in the regulation of protein metabolism in women: effects of menopausal status and hormone replacement therapy.
    Toth MJ; Sites CK; Matthews DE
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E639-46. PubMed ID: 16684855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V; Sangthawan M
    J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative.
    Chen Z; Bassford T; Green SB; Cauley JA; Jackson RD; LaCroix AZ; Leboff M; Stefanick ML; Margolis KL
    Am J Clin Nutr; 2005 Sep; 82(3):651-6. PubMed ID: 16155280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Vacca F; Genazzani AR
    Maturitas; 2005 Feb; 50(2):91-7. PubMed ID: 15653005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
    Kagan R; Abreu P; Andrews E
    Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus.
    Swift JA; Conway P; Purdie DW
    Curr Med Res Opin; 2005 Dec; 21(12):2051-61. PubMed ID: 16368056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation.
    Reuben DB; Palla SL; Hu P; Reboussin BA; Crandall C; Herrington DM; Barrett-Connor E; Greendale GA
    Am J Med; 2006 Feb; 119(2):167.e1-8. PubMed ID: 16443423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
    Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
    Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.